Todays Biggest Pre-Market Stock Movers 10 Top Gainers and Losers on Monday

MYMDDelisted Stock  USD 1.82  0.02  1.09%   
About 61% of MyMD Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in MyMD Pharmaceuticals suggests that many traders are alarmed regarding MyMD Pharmaceuticals' prospects. The current market sentiment, together with MyMD Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use MyMD Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
  
Its time to start off the week with a breakdown of the biggest pre-market stock movers worth reading about on Monday morning

Read at investorplace.com
sbwire news
  

MyMD Pharmaceuticals Fundamental Analysis

We analyze MyMD Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MyMD Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MyMD Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Net Asset

Net Asset Comparative Analysis

MyMD Pharmaceuticals is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.

MyMD Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with MyMD Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of MyMD Pharmaceuticals could also be used in its relative valuation, which is a method of valuing MyMD Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

MyMD Pharmaceuticals Related Equities

UBXUnity Biotechnology   4.17   
0%
91.0%
RXRXRecursion Pharmaceuticals   3.58   
0%
78.0%
GOVXGeoVax Labs   2.26   
0%
49.0%
DSGNDesign Therapeutics   2.25   
0%
49.0%
BOLTBolt Biotherapeutics   2.00   
0%
43.0%
KZRKezar Life   1.86   
0%
40.0%
NVCTNuvectis Pharma   1.53   
0%
33.0%
XBIOXenetic Biosciences   1.47   
0%
32.0%
REPLReplimune   1.30   
0%
28.0%
LYRALyra Therapeutics   1.18   
0%
25.0%
GOSSGossamer Bio   0.48   
0%
10.0%
REVBRevelation Biosciences   0.33   
0%
7.0%
AVIRAtea Pharmaceuticals   0.31   
0%
6.0%
PASGPassage Bio   0.15   
0%
3.0%
SRZNSurrozen   0.08   
0%
1.0%
NBYNovaBay Pharmaceuticals     
0%
1.0%
KRONKronos Bio     
1.0%
0%
LGNDLigand Pharmaceuticals   0.37   
8.0%
0%
LYELLyell Immunopharma   1.61   
35.0%
0%
ORICOric Pharmaceuticals   1.68   
36.0%
0%
KROSKeros Therapeutics   2.39   
52.0%
0%
LRMRLarimar Therapeutics   4.55   
100.0%
0%
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
You can also try the CEOs Directory module to screen CEOs from public companies around the world.

Other Consideration for investing in MyMD Stock

If you are still planning to invest in MyMD Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MyMD Pharmaceuticals' history and understand the potential risks before investing.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets